Chicken Newcastle Disease Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2035

Chicken Newcastle Disease Vaccine Market

The future of the global chicken newcastle disease vaccine market looks promising with opportunities in the chicken and adult chicken markets. The global chicken newcastle disease vaccine market is expected to reach an estimated $5.5 billion by 2035 from $3.6 billion in 2027 with a CAGR of 5.4% from 2027 to 2035. The major drivers for this market are the rising demand for poultry product and the advancements in vaccine technology.

• Lucintel forecasts that, within the type category, live vaccine is expected to witness higher growth over the forecast period due to rising demand for rapid and long-lasting immunity in poultry flocks is boosting the adoption of live vaccines.
• Within the application category, adult chicken is expected to witness the higher growth due to growing focus on long-term flock immunity is encouraging regular booster vaccinations in adult chickens.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to high concentration of large poultry farms in southeast Asia and China.

Emerging Trends in Chicken Newcastle Disease Vaccine Market

During the period of 2025 to 2027, the chicken newcastle disease vaccine market is expected to shift away from a focus on vaccine volume to vaccine prevention which is strain specific, thermostable, and digitally monitored. Poultry integrators have recently focused more on reducing losses in the field and consistent vaccine deliveries, while government organizations have focused more on providing vaccine efficacy. These are consistent with Lucintel's market focus.

• Thermostable Vaccines: Vaccine formulations that are able to withstand interruptions in cold-chains had continued research and development within manufacturing sectors in 2025. These have the potential of improving vaccine coverage and reducing vaccine waste in the small holder poultry systems in Africa and Asia where cold-chain electricity and transport infrastructure are still undeveloped.
• Strain Matching: In 2025, the Newcastle disease surveillance activities coordinated by WOAH and national veterinary laboratories are expected to place greater emphasis on cases that are genetically related and circulating with newer variants of the Newcastle disease virus. Improved performance and pricing of vaccines is expected in the near future (3 to 5 years) based on the improved field performance of Newcastle disease vaccines.
• Digital Vaccination Management: Within 2025, large poultry companies adopted digital systems for maintaining vaccine records, tracking vaccines through bar codes, and reporting data from the field. Digital traces of vaccine coverage will likely affect the purchasing of vaccines because poultry integrators are expected to demand coverage during the multi-site operations.
• Automation and Scale: Vaccine manufacturers have made significant investments to provide improvements in production flexibility, process automation and controls, and most importantly shortened production cycles. Production plants focus on batch sizes of 100,000 vaccine doses or more. Manufacturing efficiency will be critical as vaccine pricing and competition increases in developing markets.
• Integrated Prevention: By 2026, buyers will assess Newcastle disease vaccines in relation to biosecurity, diagnostic, and antimicrobial stewardship protocols, rather than as stand-alone products. This bundled approach will redefine competition among suppliers. The aim for measurable reductions in mortality, downtime, and disruptions to trade provides an opportunity for competitive advantage.

From 2025 to 2027, the preference for thermostable, differentiated Newcastle disease vaccines paired with surveillance data will dominate the market. Local strain matching that assures reliable field delivery will give market share. The market pressure will remain the same, but the economics of prevention will favor vaccination against outbreaks that negatively impact trade. The combination of strong regulatory, manufacturing, and distribution systems will separate the more established players from the less established players on a global scale.

Recent Developments in the Chicken Newcastle Disease Vaccine Market

Demand for Chicken Newcastle disease vaccines is projected to grow rapidly between 2025 and 2027 as poultry producers focus on reducing production costs associated with vaccine administration, lessening the duration of vaccination cycles, and preventing diseases. Lucintel has identified growing demand for thermostable vaccines, vector vaccines, and vaccines tailored toward intensive broiler production. Regulations are more stringent, while capacity additions in emerging markets offer greater access and reshape market dynamics for suppliers.

• Investing in Thermostable Vaccines: In January 2025, Ceva built new capacity for the production of temperature resistant poultry vaccines in Hungary. This investment is meaningful because vaccines that maintain their effectiveness are easier to distribute to countries with poor infrastructure and long stretches of warm weather.
• Vector Vaccines: Boehringer Ingelheim continued the 2025 market launch of Vaxxitek HVT+ND, which provides Newcastle disease and Marek's disease protection in a single vaccine. This vaccine offers protection against two diseases, which, when administered in the hatchery, could provide better value for money poultry producers when compared with competing offerings.
• Government-subsidized Vaccination Programs: In 2025, the Indian livestock authorities undertook several government-funded poultry disease control programs and included Newcastle disease control in their state surveillance and vaccination efforts. The government's procurement program creates a stable demand, encouraging local vaccine manufacturers.
• Increase in Regional Production: In response to government policies on Biosecurity, Chinese veterinary biologics vaccine manufacturers began producing more poultry vaccines in 2025. More vaccine availability will also lead to price competition by multinational suppliers, while improving access to better quality poultry vaccines.
• Data Integrated Vaccination Systems: In 2025, the major poultry integrators built systems for monitoring hatchery production and providing client records. This improved record keeping better guided vaccination decisions and improved contracts for integrated disease control programs.

The market is transitioning away from purchasing vaccines based on volume, toward buying vaccines based on outcomes with an outcome-based disease prevention purchase model. The suppliers who adopt this model will likely thrive over the local suppliers of vaccines. In addition to local manufacturing, field-service capability is valuable. Producing vaccines is challenging due to the logistics of transport. The removal of vaccines' costs will not grant broiler integrators lower feed conversion losses and mortality rates. Evidences and reliability in delivery will best reign. Integrating vaccination programs will help laboratories sell more vaccines.

Strategic Growth Opportunities in the Chicken Newcastle Disease Vaccine Market

The market for chicken Newcastle disease vaccine is changing due to increasing biosecurity costs, disease outbreaks, and the need to sustain production. Between 2024 and 2026, faster diagnostics, regional manufacturing, and new delivery methods will create market disruptions. Lucintel has noticed that customers care less about the volume of doses and more about the outcome of the vaccination.

• Specialty Poultry: Customized vaccines for specialty poultry (backyard, gamebirds, breeder birds) can extend the market beyond integrators. WOAH's March 2025 disease situation report listed Newcastle disease as an internationally notifiable disease. This segment of the market will generate recurring sales as mixed cropping and increased surveillance require more resources.
• Premium Thermostable Formulations: Thermostable (heat-resistant) products can be used in markets where the lack of an adequate cold chain creates a barrier to vaccine delivery. In June 2025, the Indian poultry industry continued to develop infrastructure to serve over 1.5 billion birds. Improved stability will facilitate rural delivery and reduce wastage over the next 3-5 years.
• Regional Manufacturing: Supply times can be reduced by local fill-finish along with the production of antigens. In February 2025, there was a high dependence on imported veterinary biologics in many African countries. Regional manufacturing will improve supply and create new revenues from contract manufacturing.
• Digital Vaccination Services: Integrators can purchase vaccination services that provide scheduling, traceability, and advisory based on serology along with the vaccines. In 2025, a field program covering more than 100 commercial flocks demonstrated the utility of digital batch monitoring. Subscription models will provide a greater return based on improved flock performance.
• Customized Combination Vaccines: Creating vaccines to counter Newcastle and other priority pathogens simultaneously can help control operational costs related to labor and time. In September 2025, many Asian producers said that within their commercial broilers, they started using either combination programs or two-dose programs. Customized combination vaccines will achieve market share over the competition in regions/markets with welfare and labor control measures.

In the next five years, we expect the market leaders to shift their approach and sell poultry disease control as a complete service rather than relatively inexpensive vials of vaccine. We expect that the new markets will be created as a result of more localized manufacturing, better field data, and tailored formulations of products for specific poultry farms. Regulatory framework will continue to be the most significant restraint. Companies that integrate diagnostics, vaccinations, and measurable flock performance data will continue to improve their profit margins and retain customers globally.

Chicken Newcastle Disease Vaccine Market Drivers and Challenges

Growth in Newcastle disease vaccine demand is attributable to changes in poultry consumption patterns, outbreaks of new diseases, new technologies, modern manufacturing processes, and robustness in animal health regulations. Poverty eradication, cold chain logistics, inequity in veterinary services, and rapidly mutating poultry viruses are some of the challenges. According to Lucintel, the most important drivers of competition in this market are innovation, lower prices, and large-scale immunization.

The factors responsible for driving this market include :

• Growing Demand for Poultry: Rising demand for affordable sources of protein drives producers to develop measures to protect their flocks' productivity through routine vaccination. Global poultry meat production for 2025 was projected at over 140 million metric tons, increasing the economic value of disease prevention. The next 3-5 years should see greater adoption of vaccines due to protection of the productivity of small holder poultry flocks in urbanizing and rapidly growing populations of Asia, Africa, and Latin America.
• New Technologies for Vaccine Production: Protection, ease of administration, and greater efficacy in the field are some of the desired characteristics for new vaccine technologies. In March 2025, the research on several candidates for ND vaccine was in progress to enhance mucosal immunity and reduce viral shedding. The next 3 to 5 years should see the adoption of new technologies by commercial and small holder poultry producers.
• Regulatory and Disease-control Support: Government-backed vaccination programs, veterinary disease surveillance, and international standards for disease control make producers more likely to adopt approved Newcastle disease vaccines. In 2025, Newcastle disease was still a notifiable disease in various poultry-producing regions, illustrating the need for concerted vaccination and surveillance efforts. Increased biosecurity measures and public sector campaigns in the next three to five years are expected to create greater demand for approved vaccines in more vulnerable production systems.
• Sustainability and Productivity Requirements: Vaccination reduces the mortality of the target population, thereby improving feed conversion. Resource losses due to outbreaks are also limited. In 2025, leading commercial poultry operations continued to prioritize lower resource use, such as feed, water, and energy, for each kilogram of output, which further heightened the importance of preventive health management. In the next three to five years, target setting for greater productivity alongside limited growth in resources will make vaccination a primary element of effective poultry farming.
• Manufacturing Efficiency and Distribution Expansion: Higher vaccine batch size capacity enables distribution from multiple fill-finish facilities, improved thermostability, and digital systems for inventory management. In 2025, manufacturers continued to invest in biologics capacity and temperature-controlled supply chains to meet the growing poultry market demand. In the next three to five years, expected improvements in efficiency will lower the cost of vaccine and improve availability, thus decreasing stockouts in rural settings with limited Cold Chain logistics.

The challenges facing this market include:

• Limited Cold-chain and Veterinary Infrastructure: There is limited cold-chain and veterinary infrastructure in rural areas, lacking electricity, paved roads, efficient transport, trained vaccinators, and diagnostics. In 2025, smallholder farms/production accounted for a large percentage of poultry production in the developing world where the supply of electricity and roads was insufficient. In the next 3-5 years it is expected that these infrastructure gaps will result in the loss of potency of vaccines, increased errors in the administration of vaccines, and uneven penetration in the market unless thermostable vaccines and services are made available.
• Price and Production Sector Pressure: Small-scale production of poultry is a low margin enterprise, often resulting in the decision to not vaccinate when there are cost increases for vaccine, labor, transport, and vet services. For the production of poultry in 2025, price increases on feed were a major constraint to the production of poultry, thus limiting the available budget to cover preventative health care measures. In the next 3-5 years it is expected that the premium vaccine will not be chosen due to inflation, currency differences and a fragmented buying sector, while there will be an increase in multi-dose and public procurement of vaccines.
• The Impact of Field Viruses and Inconsistent Protection: There are many factors which impact the performance of vaccines including the nature of field (wildtype) viruses, differences in the flock's immunity, poor vaccination practices, and poor biosecurity. In 2025, laboratories reported different lineages of viruses in many poultry producing areas, emphasizing the need for more surveillance and challenging vaccine efficacy studies. In the next 3-5 years, vaccine manufacturers will need to improve vaccine matching and booster strategies, develop better diagnostics, and address vaccine education to improve confidence in vaccination programs.

Chicken newcastle disease vaccine market potential can be attributed to increasing poultry production, growing disease awareness, improved biotechnology, and higher efficiency demands. Challenges to market growth can potentially be attributed to limited infrastructure, affordability, lack of integration in farmland, and continued diversification of viruses. Success in this market can be attributed to affordable formulations, thermal stability, and reliable surveillance. Coordination of regulations and extension services can be additional market enablers. The best market opportunities over the next 3-5 years can be attributed to combination of protection, convenient dosing, and stable distribution. Public vaccination and farmer education can be attributed to improvement in coverage and reduction in outbreaks whilst maintaining stable food supplies and improving economic livestock production in developing and developed markets.

List of Chicken Newcastle Disease Vaccine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies chicken newcastle disease vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the chicken newcastle disease vaccine market companies profiled in this report include-

• Boehringer-Ingelheim
• Merial
• CEVA
• QYH Biotech
• Merck Animal Health

Chicken Newcastle Disease Vaccine Market by Segment

The study includes a forecast for the global chicken newcastle disease vaccine market by type, application, and region.

Chicken Newcastle Disease Vaccine Market by Type [Value ($B) from 2019 to 2035]:

• Live Vaccine
• Inactivated Vaccine

Chicken Newcastle Disease Vaccine Market by Application [Value ($B) from 2019 to 2035]:

• Chicken
• Adult Chicken

Chicken Newcastle Disease Vaccine Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Chicken Newcastle Disease Vaccine Market

Controlling Newcastle disease is the result of enhanced poultry biosecurity and regional vaccination programs coupled with improved biologics manufacturing. Decisions related to supply will be based on critical regulatory approvals, manufacturing updates, and partnerships on vaccine platforms. According to Lucintel's latest analysis, at the country level, execution will be key for the next several years.

• United States: USDA APHIS approved licenses to commercially produce and sell Newcastle disease vaccines (January 2025). Commercial suppliers continued to produce and sell both live and inactivated Newcastle disease vaccines for layers, broiler breeders, and backyard poultry.
• China: Newcastle disease vaccines and other vaccines for the prevention of other poultry diseases continued to be a part of the Chinese Ministry of Agriculture and Rural Affairs' vaccination programs (March 2025). Registration of locally produced vaccines will impact procurement, the scale of production, and the substitution of imported biological materials.
• Germany: Authorities implemented the EU's animal health legislation (February 2025). Boehringer Ingelheim and MSD Animal Health supplied Newcastle disease products through approved European veterinary supply channels. Germany is important because of its approved manufacturing, supply, and export base. For all European supply chains, compliance and capacity will be important.
• India: India's Department of Animal Husbandry and Dairying reported on livestock health programs and control activities for chicken pox and poultry vaccination. Indian companies continued to supply commercial farms with live Newcastle vaccines (April 2025). The public programs procurement and domestic production will become important since India's growing chicken production requires large volumes that are available locally and with short delivery times.
• Japan: Japan continued its legally permitted control of poultry diseases and imports and Newcastle vaccination in prefectures with biosecurity. The country reported 47 chicken farms infected with highly pathogenic avian influenza during the 2024-2025 season (March 2025). This policy framework will continue demand for Newcastle vaccines and enhance domestic stockpile for the next 3 to 5 years.

Features of the Global Chicken Newcastle Disease Vaccine Market

• Market Size Estimates: chicken newcastle disease vaccine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: chicken newcastle disease vaccine market size by type, application, and region in terms of value ($B).
• Regional Analysis: chicken newcastle disease vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the chicken newcastle disease vaccine market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the chicken newcastle disease vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the chicken newcastle disease vaccine market by type (live vaccine and inactivated vaccine), application (chicken and adult chicken), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?